We are live on
!
Find out more
PAWC
P.A.W. Capital Portfolio holdings
AUM
$131M
1-Year Est. Return
46.14%
This Fund
S&P 500
This Quarter
Est. Return
+8.74%
1 Year Est. Return
+46.14%
3 Year Est. Return
+67.18%
5 Year Est. Return
+64.85%
10 Year Est. Return
+1,459.33%
AUM
$94.2M
AUM Growth
-$4.78M
(-4.8%)
Cap. Flow
-$11.6M
Cap. Flow
% of AUM
-12.36%
Top 10 Holdings %
Top 10 Hldgs %
40.89%
Holding
73
New
9
Increased
6
Reduced
17
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PVLA
Palvella Therapeutics
PVLA
|
+$1.36M |
| 2 |
Magnite
MGNI
|
+$1.06M |
| 3 |
Krystal Biotech
KRYS
|
+$503K |
| 4 |
Cue Biopharma
CUE
|
+$482K |
| 5 |
Gaia
GAIA
|
+$359K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SMLR
Semler Scientific
SMLR
|
+$1.69M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$1.13M |
| 3 |
ATTU
Attunity Ltd
ATTU
|
+$1.02M |
| 4 |
Akebia Therapeutics
AKBA
|
+$998K |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$951K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.35% |
| 2 | Healthcare | 15.54% |
| 3 | Communication Services | 14.8% |
| 4 | Industrials | 10.95% |
| 5 | Consumer Staples | 10.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ATTU
1
DELISTED
Attunity Ltd
ATTU
| $4.53M | 4.81% |
240,000
-60,000
| -20% | -$1.02M |
|
2
Allot
ALLT
$372M
| $4.33M | 4.59% |
700,000
-20,000
| -3% | -$117K |
|
|
MNDT
3
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $4.25M | 4.51% |
250,000
| – | – |
|
|
RCM
4
DELISTED
R1 RCM Inc. Common Stock
RCM
| $4.06M | 4.31% |
400,000
| – | – |
|
5
Chegg
CHGG
$110M
| $3.84M | 4.07% |
135,000
-15,000
| -10% | -$447K |
|
|
QUOT
6
DELISTED
Quotient Technology Inc
QUOT
| $3.72M | 3.95% |
240,000
| – | – |
|
7
Marchex
MCHX
$76.2M
| $3.58M | 3.8% |
1,287,449
-12,551
| -1% | -$35.9K |
|
|
EFII
8
DELISTED
Electronics for Imaging
EFII
| $3.58M | 3.8% |
105,000
-10,000
| -9% | -$339K |
|
|
9
Gaia
GAIA
$46.8M
| $3.39M | 3.6% |
220,000
+20,000
| +10% | +$359K |
|
10
Mitek Systems
MITK
$754M
| $3.24M | 3.44% |
460,000
+35,000
| +8% | +$289K |
|
|
CARB
11
DELISTED
Carbonite Inc
CARB
| $3.21M | 3.41% |
90,000
| – | – |
|
|
EMKR
12
DELISTED
Emcore Corp
EMKR
| $3.13M | 3.33% |
66,000
-4,000
| -6% | -$195K |
|
13
Varonis Systems
VRNS
$4.59B
| $2.93M | 3.11% |
120,000
-15,000
| -11% | -$364K |
|
|
VRTU
14
DELISTED
Virtusa Corporation
VRTU
| $2.69M | 2.85% |
50,000
-5,000
| -9% | -$272K |
|
15
Kratos Defense & Security Solutions
KTOS
$8.74B
| $2.22M | 2.35% |
150,000
| – | – |
|
|
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $1.95M | 2.07% |
23,900
-16,100
| -40% | -$1.13M |
|
17
Ares Capital
ARCC
$13.5B
| $1.72M | 1.82% |
100,000
| – | – |
|
18
BlackRock TCP Capital
TCPC
$273M
| $1.64M | 1.74% |
115,000
| – | – |
|
|
ASPU
19
DELISTED
ASPEN GROUP, INC.
ASPU
| $1.56M | 1.66% |
230,000
| – | – |
|
|
SMLR
20
DELISTED
Semler Scientific
SMLR
| $1.51M | 1.61% |
42,500
-47,500
| -53% | -$1.69M |
|
21
Digital Turbine
APPS
$975M
| $1.49M | 1.58% |
1,200,000
| – | – |
|
22
uniQure
QURE
$3.03B
| $1.46M | 1.55% |
40,000
+5,000
| +14% | +$186K |
|
|
PVLA
23
Palvella Therapeutics
PVLA
$1.99B
| $1.4M | 1.49% |
+3,125
| New | +$1.36M |
|
24
Galmed Pharmaceuticals
GLMD
$5.13M
| $1.22M | 1.3% |
500
-28
| -5% | -$65.5K |
|
25
LendingTree
TREE
$447M
| $1.15M | 1.22% |
5,000
| – | – |
|
Similar funds
EIM
CIP
AC
ADEF
LC
EWP
OIM
EPI
P.A.W. Capital's Q3 2018 Portfolio in Review
As of Q3 2018, P.A.W. Capital held 73 positions worth $94.2M, down 4.8% from $99M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
P.A.W. Capital withdrew a net $11.6M in Q3 2018, closing 7 positions and reducing 17 holdings. Its most notable exit was Akebia Therapeutics, an estimated $998K position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Communication Services.
Against the trend, P.A.W. Capital opened a new position in Palvella Therapeutics worth $1.4M.
- P.A.W. Capital's largest Q3 2018 buy was Palvella Therapeutics: 3,125 shares worth $1.4M.
- P.A.W. Capital added most to Cue Biopharma in Q3 2018, an estimated $482K increase.
- P.A.W. Capital's biggest Q3 2018 reduction was Semler Scientific, cutting an estimated $1.69M.
- P.A.W. Capital fully exited Akebia Therapeutics in Q3 2018, selling an estimated $998K.
- P.A.W. Capital's ten largest holdings make up 41% of its $94.2M portfolio in Q3 2018.
- P.A.W. Capital opened 9 new positions and closed 7 in Q3 2018.
- P.A.W. Capital's portfolio value fell 4.8% quarter-over-quarter to $94.2M.
Based on P.A.W. Capital's 13F filing for Q3 2018, filed 24 Oct 2018.